Skip to content

Momenta downgraded to neutral by Barclays

May 22, 2017

Analyst Douglas Tsao cited the likelihood generic manufacturers, most notably Mylan, could win approval for generic Copaxone in the coming months before Momenta and its partner Sandoz.

 

Barclays downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Overweight to Equalweight with a price target of $17.00 (from $20.00).

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: